Actively Recruiting
Genetic Testing for Cancer Risk in Women, Trans Men, and Non-Binary People with Female Reproductive Organs Early Detection and Prevention of Breast, Ovary, Bowel, and Womb Cancers
Led by Queen Mary University of London · Updated on 2026-03-27
6000
Participants Needed
1
Research Sites
574 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating genetic testing for Cancer Susceptibility Genes CSGs including BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, and MSH6 to identify women, trans men, and non-binary people with female reproductive organs who may have an increased risk of breast, ovary, bowel, and womb cancers. These cancers represent half of all cancers in women and some cases are linked to inherited genetic changes. The study aims to offer genetic testing to a broad population regardless of family or personal cancer history, addressing gaps in current testing availability and improving early detection and prevention options. Participants will be offered genetic testing through a fully digital approach using a specially developed app. After completing consent and a health questionnaire in the app, participants can receive a saliva-based test kit by mail to provide a sample for genetic analysis. The study will assess how many people choose to have testing, how many have genetic changes, and their experiences using the app. It will also monitor decisions on managing cancer risk, including screening and preventive measures, and evaluate the apps impact on quality of life, satisfaction, and mental well-being. During the study, participants will complete questionnaires about their experience and psychosocial wellbeing at several time points up to 12 months. Researchers will track uptake of risk management options annually for up to eight years and measure cost-effectiveness and genetic testing outcomes. A small group may be invited for interviews about their decision-making and study participation. This study is sponsored by Queen Mary University of London and aims to improve understanding of population-based genetic testing for cancer prevention.
CONDITIONS
Brief Title
Population Based Germline Testing for Early Detection and Prevention of Cancer
Research Team
R
Ranjit Manchanda, PhD
C
Caitlin Fierheller, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here